

U.S. Food and Drug Administration
Division of Pharmaceutical Quality Operations I
10 Waterview Blvd, 3rd FL
Parsippany, NJ 07054
Telephone: (973) 331-4900
Fax: (973) 331-4969
www.fda.gov

July 29, 2019

Michael Segal, CEO PharmScript, LLC 150 Pierce Street Somerset, NJ 08873

Dear Mr. Segal:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, PharmScript, LLC, located at 150 Pierce Street, Somerset, NJ 08873-4185, from July 30, 2018, to August 7, 2018, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter sent to the New Jersey State Board of Pharmacy for follow up.

When the Agency considers an inspection to be "closed" under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Compliance Officer, James Mason, at 570 262-0519, or by email at James.Mason@fda.hhs.gov.

Sincerely,

Stephanie Digitally signed by Stephanie T. Durso -5 DN: c-US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9-2342.19200300.100.1.1=13001 94209, cn=Stephanie T. Durso -5 Date: 2019.07.29 13:31:10 -04'00'

Stephanie Durso Director Compliance Branch OPQO Division I/New Jersey District Office